Han et al. analyzed 148 advanced non-small cell lung cancer treated with different anticancer drug to investigate whether polymorphisms of p53 codon 72 (Arg72Pro) and MDM2 SNP309 (309T>G) affect p53 expression and the clinical outcome of patients (35). Here, TP53 is linked to non-small cell lung carcinoma.